Giotrif 40 mg (Afatinib (Afatinib Dimaleate) TABLET) 40 MG

Giotrif 40 mg tablets contain afatinib dimaleate, a targeted therapy used in cancer treatment. This oral medication is designed to inhibit specific proteins involved in cancer cell growth.

Strength

40 MG

Pack Size

14/28

Manufacturer / TM Owner

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Giotrif 40 mg tablets are primarily used in the treatment of certain types of cancer. Afatinib, the active ingredient, works by targeting and blocking specific proteins that help cancer cells grow and spread. This medication is often prescribed for non-small cell lung cancer and other conditions as determined by a healthcare provider. Patients may wonder, 'What is Giotrif used for?' and the answer lies in its ability to interfere with cancer cell proliferation.

Side Effects

Common effects of Giotrif 40 mg tablets may include skin reactions, diarrhea, and nausea. Some patients might experience appetite loss or fatigue. These effects can vary widely among individuals and are not exhaustive. Always consult a healthcare professional for personalized advice.

Precautions & Warnings

Giotrif 40 mg tablets should be handled with care. Store them at room temperature, away from moisture and heat. Keep the medication out of reach of children and pets. Follow the prescribed dosage and administration instructions provided by your healthcare provider.

Avoid Interactions

Giotrif 40 mg tablets may interact with certain medications, including those that affect liver enzymes. Alcohol and other substances that impact liver function should be avoided. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.

Frequently Asked Questions

Giotrif is used in the treatment of certain types of cancer, primarily non-small cell lung cancer.

Giotrif tablets are taken orally, usually once daily. Follow the instructions provided by your healthcare provider.

Common side effects may include skin reactions, diarrhea, nausea, appetite loss, and fatigue.

It is generally advised to avoid alcohol while taking Giotrif, as it may interact with the medication.

Store Giotrif tablets at room temperature, away from moisture and heat, and keep them out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.